Immunocyte damage
Conditions
Interventions
Dose groups of ? 0.1Gy, 0.1-0.3Gy, ? 0.3Gy:N/A
Sponsors
Zhujiang Hospital, Southern Medical University.
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18-80 years, gender is not limited; (2) Patients who need to accept interventional therapy; (3) Voluntary participation in the clinical trial, understanding and signing the informed consent;
Exclusion criteria
Exclusion criteria: (1) Those who plan to undergo interventional therapy again and continue to receive radiation therapy; (2) Comply with severe cardiovascular, liver, blood system,neuroendocrine system diseases, Alanine aminotransferase and alkaline phosphatase 1.5 times highter than normal value, serum creatinine > 2 mg/dl (194.5 umol/L), serum potassium > 5.5 mol/L; cancer patients;psychiatric patients; (3) Persons with genetic or DNA repair syndrome or family history of disease; (4) Persons previously exposed to medical/occupational radiation; (5) Pregnant or pregnant women and lactating women; (6) Allergic constitution, or known drug allergy; (7) Patients with cancer or immunodeficiency diseases, leukocyte and lymphocyte abnormalities; (8) Participate in other drug clinical trial within one month; (9) Patients who can not complete the study or comply with the requirements of the study (due to management reasons or other reasons) according to the judgement of the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lymphocyte micronucleus rate;Lymphocyte aberration rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumors or immune system diseases occured; | — |
Countries
China
Contacts
Public ContactFu Xiaohua
Zhujiang Hospital, Southern Medical University.
Outcome results
None listed